ENABLE 2 Pivotal CML Design Disclosed
Enliven reported FDA alignment on the design of ENABLE-2, a planned randomized Phase 3 trial of relcobatinib in previously treated chronic myeloid leukemia. The event specifies a testable pivotal comparison and endpoint but supplies…
